

OncoOmicsDX : Publications and Poster Presentation in Clinical Oncology Conferences

Peer-review publications:

Name	Year	Journal	Institutions	Contact PI	Type of cancer	Paper Type	PMID#
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.	2023	JCO Precision Oncology	Stanford University	Calvin Kuo	Pancreatic	Clinical	37079860
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance	2021	Clin Cancer Research	Memorial Sloan Kettering Cancer Center	Alexander Drilon	Lung	Clinical	33172896
Quantitative Multiplexed Proteomics Could Assist Therapeutic Decision Making in Non-Small Cell Lung Cancer Patients with Ambiguous ALK Test Results	2021	Cancers (Basel)	Catholic University of Korea	Tae-Jung Kim	Lung	Clinical	34066104
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S	2021	Tumori	University of Milan, Italy	Filippo Pietrantonio	GEC	Clinical	32522106
EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer	2020	Cancer discovery	Memorial Sloan Kettering Cancer Center	Rona Yaeger	Colorectal	Clinical	32430388
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers	2020	Cancer discovery	Memorial Sloan Kettering Cancer Center	Bob Li	Lung	Clinical	32213539
Overcoming hypoxia-induced functional suppression of NK cells	2020	J Immunother Cancer	National Cancer Institute	James Hodge		Pre-Clinical	32345623
High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies	2020	EBioMedicine	Institut Bergonié, Bordeaux, France	Antoine Italiano	Sarcoma	Clinical	33254023
Characterization of MGMT and EGFR Protein Expression in Glioblastoma and Association With Survival	2020	Journal of NeuroOncology	Memorial Sloan Kettering Cancer Center	Andrew Lin	Brain	Clinical	31823165
EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer.	2019	Cancer discovery	Memorial Sloan Kettering Cancer Center	Maurizio Scaltriti	GEC	Clinical	30463996
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.	2019	The LANCET Oncology	Institut Bergonié, France	Antoine Italiano	Sarcoma	Clinical Trial	31331699
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.	2019	European journal of Cancer	Fondazione IRCCS Istituto Nazionale dei Tumori, Italy	Filippo Pietrantonio	Colorectal	Clinical Trial	30579113
Targeted Multiplex Proteomics for Molecular Prescreening and Biomarker Discovery in Metastatic Colorectal Cancer	2019	Scientific Reports	Vall'd Hebron Institute of Oncology	Paolo Nuciforo	CRC	Clinical	31537838
Data-independent acquisition mass spectrometry to quantify protein levels in FFPE tumor biopsies for molecular diagnostics.	2019	Journal of Proteome Research	University of Washington	Michael MacCoss	GEC Colorectal	Technical	30481034
Translation and evaluation of a pre-clinical 5-protein response prediction signature in a breast cancer phase Ib clinical trial.	2019	PLoS One	Roche Pharmaceutical	Axel Ducret	Breast	Pre-Clinical	30897176
Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.	2018	Cancer discovery	University of Chicago	Daniel Catenacci	GEC	Clinical	29449271
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition.	2018	Nature medicine	Harvard Medical School Univ. of Chicago School of Medicine	Adam Bass Daniel Catenacci	GEC	Pre-Clinical	29808010
Ado-trastuzumab emtansine for patients with HER2- mutant lung cancers: Results from a phase II basket trial	2018	Journal of Clinical Oncology	Memorial Sloan Kettering Cancer Center	Maurizio Scaltriti	Lung	Clinical Trial	29989854
Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies.	2018	Journal of Proteomics	OncoPlex Diagnostics	Yeoun Jin Kim		Technical	29684684
Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.	2018	Head & neck	Harvard Medical School Johns Hopkins University Naval Medical Center	Jong Chul Park Hyunseok Kang	Salivary duct	Case report	30478962

Name	Year	Journal	Institutions	Contact PI	Type of cancer	Paper Type	PMID#
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.	2018	Tumori Journal	Gustave Roussy, France	Jean-Charles Soria	GEC	Case report	29714649
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.	2017	Nature	Memorial Sloan Kettering Cancer Center	Neal Rosen, Rona Yaeger	Melanoma Lung	Pre-Clinical	28783719
An approach to suppress the evolution of resistance in BRAF ^{V600E} -mutant cancer.	2017	Nature medicine	Memorial Sloan Kettering Cancer Center	Neal Rosen, Piro Lito	Melanoma Lung	Pre-Clinical	28714990
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.	2017	Annals of Oncology	Seoul National University Hospital University of Chicago	Yung-Jue Bang Daniel Catenacci	GEC	Clinical Trial	27687309
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.	2017	Cancer	University of Chicago Azienda Ospedaliera, Italy	Daniel Catenacci Francesco Granziano	GEC	Clinical	27926778
Proof of the quantitative potential of immunofluorescence by mass spectrometry.	2017	Laboratory Investigation	Yale University Medical School	David Rimm	Multiple	Technical	28092364
Quantification of anaplastic lymphoma kinase protein expression in non-small cell lung cancer tissues from patients treated with crizotinib.	2016	Clinical Chemistry	Dartmouth-Hitchcock Medical Center	Laura Tafe	Lung	Clinical	26585927
Therapeutically induced changes in HER2, HER3, and EGFR protein expression for treatment guidance.	2016	Journal of the National Comprehensive Cancer Network	University of Chicago	Daniel Catenacci	GEC	Case report	27160229
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH.	2016	Gastric Cancer	University of Chicago	Daniel Catenacci	GEC	Clinical	26581548
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.	2016	Molecular Oncology	Memorial Sloan Kettering Cancer Center Vall d'Hebron Institute of Oncology, Spain	Maurizio Scaltriti Paolo Nuciforo	Breast	Clinical	26422389
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.	2014	Molecular Cancer Therapeutics	University of Chicago	Ravi Salgia	Lung	Pre-Clinical	24327519
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.	2014	PLoS One	University of Chicago National Institute of Health (NIH)	Daniel Catenacci Donald Bottaro	GEC	Clinical	24983965
Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma	2014	Applied Immunohistochemistry & Molecular Morphology	University of California, San Francisco	Steven Dubois	Ewing sarcoma	Clinical	24590121
Application of selected reaction monitoring for multiplex quantification of clinically validated biomarkers in formalin-fixed, paraffin-embedded tumor tissue.	2013	The Journal of Molecular Diagnostics	OncoPlex Diagnostics National Cancer Institute	David Krizman Todd Hembrough	Breast	Technical	23672976
Selected Reaction Monitoring (SRM) analysis of Epidermal Growth Factor Receptor (EGFR) in formalin fixed tumor tissue.	2012	Clinical proteomics	OncoPlex Diagnostics Ontario Cancer Institute, Canada	Jon Burrows Ming-Sound Tsao	Breast Lung	Technical	22554165
Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues.	2011	Journal of Proteome Research	University of Pittsburgh	Thomas Conrads	Breast	Technical	21155598
mTRAQ-based quantification of potential endometrial carcinoma biomarkers from archived formalin-fixed paraffin-embedded tissues.	2010	Proteomics	York University, Canada	Michael Siu	Endometrial	Technical	20661955
Proteomic analysis of formalin-fixed prostate cancer tissue.	2005	Molecular & cellular proteomics	National Cancer Institute	David Krizman	Prostate	Technical	16091476
Liquid Tissue: proteomic profiling of formalin-fixed tissues.	2005	Biotechniques	National Cancer Institute	David Krizman	Colon	Technical	16528915
The role of tissue microdissection in cancer research.	2001	The Cancer Journal	National Cancer Institute	David Krizman Michael Emmert-Buck		Review	11269646

OncoOmicsDX : Publications and Poster Presentation in Clinical Oncology Conferences

Poster Presentations:

Conference	Year	Poster Title
AACR	2024	Co-expression proteomic analysis of antibody drug conjugate receptor and payload biomarkers in breast cancer
ASCO-GI	2024	Unveiling Proteomic Diversity: A Quantitative Study of Antibody Drug Conjugate and Chemotherapy Targets in Gastroesophageal Cancer
ASCO	2023	Personalized therapy for Head and Neck Squamous Cell Carcinoma (HNSCC) utilizing tissue proteomics profiling
AACR	2023	Quantitative Proteomics of Antibody-Drug Conjugates and Chemotherapy Targets in Prostate Cancer
ASCO-GI	2023	Proteomic profiling of antibody-drug conjugate (ADC) biomarkers in pancreatic cancer
AACR	2022	Clinical Survey of TROP2 antibody drug-conjugate target and payload biomarkers in multiple cancer indications using multiplex mass spectrometry
ASCO-GI	2021	Targeted Multiplex Proteomics (TMP) and Genomics of Early-Onset Colorectal Cancer (EO-CRC)
ASCO	2020	Proteomic profiling to identify therapeutics targets in glioblastoma
AACR	2020	Quantitative Mass Spectrometry of HER2 Protein Levels Reveals High Variability within HER2 IHC Grades
AACR	2020	Molecular profiling of ovarian cancer by targeted proteomics to inform personalized therapy
ASCO-GI	2020	Expression of antibody-drug conjugates (ADC) biomarkers in colorectal cancer
ASCO-GI	2020	Integrating multiple “omics” analyses, on a triage concept, for effective case selection followed by diagnostic colonoscopy
ASCO	2018	Identifying Treatment Options for Small Cell Lung Cancer Patients with Multiplexed Clinical Proteomic Testing
ASCO	2018	Comprehensive proteomic and genomic profiling to identify therapeutic targets in adenoid cystic carcinoma
ASCO-GI	2018	Selecting Patients with Stage II or III Colorectal Cancer for 5-Fluorouracil-based Adjuvant Chemotherapy Using Proteomic Analysis
IASLC	2017	SLFN11 expression in early stage non-small cell lung cancer correlates with benefit from platinum-containing chemotherapy
SABC	2017	Identifying Patients Sensitive to Anthracycline-containing Therapy with Quantitative Proteomic and Genomic Profiling
ASCO-GI	2017	Entering the Era of Clinical Proteomics: Utilizing Multiplexed Targeted Proteomics to Identify GC Patients Who May Benefit from Docetaxel: Reevaluation of the ITACA-S trial
ASCO	2017	Identifying Responders to Temozolomide Among Patients with Metastatic Colorectal Cancer Using Proteomic Quantitation of MGMT
AACR	2017	Proteomic analysis of therapeutic biomarkers in decalcified bone metastases
AACR	2017	HER2 protein quantification in multiple cancer indications Identifies candidates for HER2 targeted therapies
AACR	2017	Using “omics” to select immunotherapy and conventional therapy combinations
IASLC	2017	Domain-specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non-Small Cell Lung Cancer
SABC	2016	Mass spectrometry-based proteomic analysis may improve identification of patients sensitive to FGFR inhibitor therapy
EORTC-NCI-AACR	2016	Clinical mass spectrometry-based proteomics unlocks personalized medicine potential from bone metastases
ASCO	2016	KRAS Gene Amplification Defines A Distinct Molecular Subgroup of Gastroesophageal Adenocarcinoma
AACR	2016	Targeted proteomic analysis for personalized treatment of muscle invasive bladder cancer
SABC	2015	Quantitative HER family proteins assessment as prognostic and predictive biomarkers in the EGF30008 clinical trial.
ASCO	2015	Quantitative measurement of HER2 levels by targeted proteomics predicts survival in gastric cancer patients treated with trastuzumab
ASCO	2015	Proteomic analysis of primary and metastatic breast cancers reveals a wide range of expression of the folate receptor, a potential drug target
ASCO	2015	Genomics, Transcriptomics, and Proteomics in the Clinical Setting: Integrating Whole Genome and RNA Sequencing With Quantitative Proteomics to Better Inform Clinical Treatment Selection
ASCO	2015	HER2 Quantification By Targeted Proteomics Compared To IHC Or ISH In Predicting Clinical Benefit From Anti-HER2 Therapy In HER2-positive Breast Cancer
AACR	2015	A novel clinical tool that provides quantitative and accurate measurement of Met protein
AACR	2015	Multiplexed Biomarker Analysis for Personalized Chemotherapeutics
AACR	2015	Development of a mass spectrometry based Antibody-Drug Conjugate biomarker panel
TAT	2015	Personalizing Patient Care Using Clinical Proteomics

Conference	Year	Poster Title
ASCO-GI	2015	Her2 expression in Gastroesophageal Cancer (GEC) FFPE Tissue using Mass Spectrometry (MS) and correlation with HER2 gene amplification
TAT	2014	Treating Chemotherapy as Targeted Therapy: Clinical validation of a quantitative multiplex assay of protein targets that modulate chemotherapeutic response
EORTC	2014	Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for the PD-L1 Protein in FFPE Samples
AACR	2014	Can Chemotherapy be Targeted Therapy? Clinical validation of a multiplexed ChemoPlex SRM assay in FFPE human tumor tissue
ASCO-Thoracic Oncology	2014	Quantification of ALK from Non-Small Cell Lung Cancer (NSCLC) FFPE Tissue by Targeted Mass Spectrometry
ASCO-GI	2014	Quantification of HER2 from Gastroesophageal Cancer (GEC) FFPE Tissue by Mass Spectrometry (MS)
ASCO-GI	2014	Quantification of MET Expression Using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue
ASCO-GI	2014	Towards personalized treatment for gastroesophageal adenocarcinoma: Strategies to address inter- and intra- patient tumor heterogeneity: PANGEA
IASLC	2014	Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for PD-L1 Protein in FFPE NSCLC Samples
IASLC	2014	Multiplexed Mass Spectrometry-based Assay to Quantify Translocation Markers from NSCLC FFPE Tissue
USCAP	2014	Quantification of ALK from Formalin-Fixed Paraffin-Embedded Non-small Cell Lung Cancer (NSCLC) Tissue by Mass Spectrometry
AACR	2013	Development of a Quantitative Gastroesophageal Cancer SRM assay for Use in FFPE Tumor Tissues
MSACL	2013	Development of a Quantitative Gastroesophageal Cancer SRM assay for Use in FFPE Tumor Tissues
SABC	2012	Mass Spectrometry Based Quantitative Analysis of the HER Family receptors in FFPE Breast Cancer Tissue
AACR	2012	Multiplexed SRM Analysis of Oncogenic Receptors in FFPE Colorectal Carcinoma Tissue
USHUPO	2012	Development of a Quantitative HER3 SRM Assay for use in Formalin-Fixed Tumor Tissues